GO:0015227 O-acyl-L-carnitine transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015227 describes the molecular function of moving O-acyl-L-carnitine (acylcarnitine) across a membrane, a critical step in fatty acid transport into mitochondria.
• This activity is essential for mitochondrial fatty acid oxidation and energy production, linking lipid metabolism to cellular respiration.
• Transporters with this activity belong to the solute carrier (SLC) family, notably SLC25A20 (CACT), which exchanges acylcarnitine for free carnitine.
• Defects in acylcarnitine transport cause carnitine-acylcarnitine translocase deficiency, a rare but severe metabolic disorder.
• Studying GO:0015227 helps researchers understand metabolic diseases, cancer metabolism, and drug interactions involving natural products.
• CRISPR-based models (knockout, knock-in, overexpression) enable precise functional dissection of genes encoding acylcarnitine transporters.
Description
O-acyl-L-carnitine transmembrane transporter activity (GO:0015227) is a molecular function that enables the transfer of acylcarnitine esters across biological membranes. Acylcarnitines are formed by condensation of carboxylic acids with carnitine and serve as the transport form for fatty acids entering the mitochondrial matrix for beta-oxidation. This activity is therefore central to energy homeostasis, particularly in tissues that rely heavily on fatty acid oxidation such as heart and skeletal muscle. Researchers study this function to understand metabolic disorders, drug-nutrient interactions, and the role of mitochondrial transport in disease. The transporter proteins mediating this activity are members of the solute carrier family, and their dysfunction has been linked to severe clinical phenotypes.
O-acyl-L-carnitine transmembrane transporter activity At A Glance
| GO ID | GO:0015227 |
|---|---|
| GO term | O-acyl-L-carnitine transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | acylcarnitine transporter activity |
| Major function | Transports acylcarnitine across membranes for fatty acid oxidation |
| Definition source | QuickGO |
| Related diseases | Carnitine-acylcarnitine translocase deficiency, metabolic disorders |
| Key transporter | SLC25A20 (CACT) |
What Is GO:0015227?
GO:0015227 is defined as enabling the transfer of O-acyl-L-carnitine from one side of a membrane to the other. O-acyl-L-carnitine is the condensation product of a carboxylic acid and carnitine and is the transport form for a fatty acid crossing the mitochondrial membrane. In simpler terms, it is the activity of a protein that carries acylcarnitine molecules across a lipid bilayer, a process essential for fatty acid oxidation.
Why Is O-acyl-L-carnitine transmembrane transporter activity Important in Cell Biology?
This activity is a cornerstone of mitochondrial fatty acid oxidation, a process that generates ATP during fasting and exercise. Without efficient acylcarnitine transport, long-chain fatty acids cannot enter mitochondria, leading to energy failure and accumulation of toxic intermediates. Clinically, impaired activity causes carnitine-acylcarnitine translocase deficiency, characterized by hypoketotic hypoglycemia, cardiomyopathy, and sudden death. Understanding GO:0015227 also informs drug development, as many natural products and drugs interact with transporters, potentially altering acylcarnitine flux and energy metabolism.
• Essential for mitochondrial fatty acid oxidation and ATP production.
• Mutations in the transporter cause carnitine-acylcarnitine translocase deficiency, a life-threatening disorder.
• Influences metabolic flexibility in heart and skeletal muscle.
• Target for understanding drug-induced metabolic toxicity.
• Plays a role in cancer metabolism and cachexia.
• Relevant to newborn screening via acylcarnitine profiles.
• Key to studying peroxisomal and mitochondrial fatty acid transport.
• Provides a model for secondary active transport mechanisms.
What Happens During O-acyl-L-carnitine transmembrane transporter activity?
Substrate Recognition and Binding
In simple terms: The transporter grabs acylcarnitine on one side of the membrane.
The transporter protein, such as SLC25A20, recognizes acylcarnitine esters with varying acyl chain lengths. Binding occurs at a specific site within the transmembrane domain, and the protein undergoes conformational changes to accommodate the substrate.
Translocation Across the Membrane
In simple terms: The transporter flips the acylcarnitine to the other side of the membrane.
Using energy from the carnitine gradient or membrane potential, the transporter moves acylcarnitine across the inner mitochondrial membrane in exchange for free carnitine. This antiport mechanism ensures continuous supply of acylcarnitine for beta-oxidation.
Release and Recycling
In simple terms: The acylcarnitine is released inside the mitochondria, and the transporter resets.
Once inside, acylcarnitine is converted back to acyl-CoA by carnitine palmitoyltransferase 2 (CPT2), and the transporter returns to its original conformation to repeat the cycle.
Regulation by Substrate Availability
In simple terms: The speed of transport depends on how much acylcarnitine is available.
Transport activity is regulated by the concentrations of acylcarnitine and carnitine, as well as by hormonal signals that control fatty acid flux, such as insulin and glucagon.
Key Genes Involved in GO:0015227 O-acyl-L-carnitine transmembrane transporter activity
The following genes encode proteins that exhibit or regulate O-acyl-L-carnitine transmembrane transporter activity, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC25A20 | Mitochondrial carnitine-acylcarnitine translocase (CACT) | Primary transporter for acylcarnitine into mitochondria; mutations cause CACT deficiency |
| CPT1A | Carnitine palmitoyltransferase 1A | Generates acylcarnitine for transport; regulates fatty acid oxidation |
| CPT2 | Carnitine palmitoyltransferase 2 | Converts acylcarnitine back to acyl-CoA inside mitochondria |
| SLC25A29 | Mitochondrial carnitine/acylcarnitine carrier-like protein | Potential alternative transporter for acylcarnitines |
| SLC22A5 | Carnitine transporter OCTN2 | Plasma membrane carnitine uptake, indirectly affecting acylcarnitine transport |
| ACADVL | Very long-chain acyl-CoA dehydrogenase | Beta-oxidation enzyme; defects lead to acylcarnitine accumulation |
| HADHA | Trifunctional protein subunit alpha | Mitochondrial fatty acid oxidation; acylcarnitine profile changes |
| HADHB | Trifunctional protein subunit beta | Mitochondrial fatty acid oxidation; acylcarnitine profile changes |
| ETFA | Electron transfer flavoprotein alpha | Fatty acid oxidation; acylcarnitine accumulation in deficiency |
| ETFB | Electron transfer flavoprotein beta | Fatty acid oxidation; acylcarnitine accumulation in deficiency |
| ETFDH | Electron transfer flavoprotein dehydrogenase | Fatty acid oxidation; acylcarnitine accumulation in deficiency |
| PPARA | Peroxisome proliferator-activated receptor alpha | Regulates fatty acid oxidation genes including transporters |
| PPARGC1A | PGC-1alpha | Master regulator of mitochondrial biogenesis and fatty acid oxidation |
| NR1H4 | Farnesoid X receptor | Regulates bile acid and lipid metabolism, affecting acylcarnitines |
| SLC25A1 | Mitochondrial citrate carrier | Related mitochondrial carrier family member |
| SLC25A10 | Mitochondrial dicarboxylate carrier | Related mitochondrial carrier family member |
| SLC25A12 | Mitochondrial aspartate/glutamate carrier | Related mitochondrial carrier family member |
| SLC25A13 | Mitochondrial aspartate/glutamate carrier | Related mitochondrial carrier family member |
How Is O-acyl-L-carnitine transmembrane transporter activity Regulated?
The activity of O-acyl-L-carnitine transmembrane transporters is regulated at multiple levels. Transcriptional control by PPARalpha and PGC-1alpha increases transporter expression during fasting or high-fat feeding. Post-translational modifications, such as phosphorylation, may alter transport kinetics. Substrate availability and the carnitine/acylcarnitine ratio also modulate activity, ensuring that fatty acid oxidation matches energy demand.
O-acyl-L-carnitine transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC25A20 | Carnitine-acylcarnitine translocase deficiency | Knockout mouse, patient-derived fibroblasts, iPSC-derived cardiomyocytes |
| CPT1A | CPT1A deficiency, metabolic syndrome | Liver-specific knockout, overexpression in hepatocytes |
| CPT2 | CPT2 deficiency, rhabdomyolysis | Knockout mouse, muscle-specific knockout |
| SLC22A5 | Primary carnitine deficiency | Knockout mouse, patient fibroblasts |
| PPARA | Metabolic syndrome, fatty liver | Knockout mouse, agonist-treated models |
Carnitine-Acylcarnitine Translocase Deficiency
Mutations in SLC25A20, which encodes the carnitine-acylcarnitine translocase, cause a severe autosomal recessive disorder. Patients present with hypoketotic hypoglycemia, hyperammonemia, cardiomyopathy, and skeletal myopathy, often leading to early death. The defect blocks mitochondrial fatty acid oxidation, resulting in accumulation of acylcarnitines in blood and impaired energy production.
Metabolic Syndrome and Diabetes
Altered acylcarnitine transport and profiles are observed in insulin resistance and type 2 diabetes. Accumulation of certain acylcarnitines is associated with impaired glucose tolerance and may contribute to lipotoxicity in skeletal muscle and liver.
Cancer Metabolism
Cancer cells often reprogram lipid metabolism, and acylcarnitine transporters can support fatty acid oxidation for energy and survival under stress. Targeting these transporters is being explored as a therapeutic strategy in cancers dependent on fatty acid oxidation.
From O-acyl-L-carnitine transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SLC25A20 loss impair fatty acid oxidation? | SLC25A20 knockout cell line (e.g., HEK293, HeLa) or mouse |
| What is the effect of a patient mutation on transport? | Point mutation knock-in of SLC25A20 variant in cell line |
| Can a tagged transporter be used for localization studies? | Knock-in of FLAG- or GFP-tagged SLC25A20 |
| Does overexpression of SLC25A20 increase acylcarnitine uptake? | Overexpression of SLC25A20 in cell lines |
| Which genes regulate acylcarnitine transport? | CRISPR library screening for modifiers of acylcarnitine levels |
| Can we model CACT deficiency in vitro? | iPSC-derived cardiomyocytes from patient or CRISPR-edited lines |
How to Study the O-acyl-L-carnitine transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS acylcarnitine profiling | Concentrations of acylcarnitine species | Newborn screening, metabolic disease diagnosis |
| Radiolabeled transport assay | Uptake of acylcarnitine into mitochondria or liposomes | Kinetic characterization of transporters |
| CRISPR knockout screening | Genes affecting acylcarnitine levels or transport | Discovery of novel regulators |
| RNA-seq | Transcript levels of transporter genes | Expression profiling under metabolic stress |
| Proteomics | Protein abundance of transporters | Validation of expression changes |
| Immunofluorescence | Subcellular localization of transporters | Confirmation of mitochondrial targeting |
| Seahorse assay | Mitochondrial respiration and fatty acid oxidation | Functional impact of transporter manipulation |
Acylcarnitine Profiling by Mass Spectrometry
Tandem mass spectrometry (MS/MS) is the gold standard for measuring acylcarnitine species in blood, urine, or cell extracts. This method quantifies the substrates of GO:0015227 and is used clinically for newborn screening of fatty acid oxidation disorders.
Transport Assays Using Radiolabeled Substrates
Isolated mitochondria or proteoliposomes reconstituted with the transporter can be used to measure uptake of radiolabeled acylcarnitine. Such assays directly assess transport activity and kinetics.
CRISPR Screening for Transport Regulators
Genome-wide CRISPR knockout or activation screens coupled with acylcarnitine measurement can identify genes that regulate transporter expression or activity, revealing novel therapeutic targets.
Transcriptomics and Proteomics
RNA-seq and quantitative proteomics can reveal changes in expression of SLC25A20 and related genes under different metabolic conditions, providing insight into regulation of GO:0015227.
How CRISPR Can Be Used to Study GO:0015227 O-acyl-L-carnitine transmembrane transporter activity
Knockout
CRISPR knockout of SLC25A20 or related genes in cell lines (e.g., HEK293, HepG2) abolishes acylcarnitine transport, leading to impaired fatty acid oxidation and accumulation of acylcarnitines. These models are valuable for studying the metabolic consequences of loss of GO:0015227.
Point Mutation
Introducing patient-specific point mutations (e.g., in SLC25A20) via CRISPR base editing or homology-directed repair allows researchers to dissect the functional impact of individual variants on transport activity and substrate specificity.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins (e.g., GFP) into the endogenous SLC25A20 locus enables real-time tracking of transporter localization and dynamics without overexpression artifacts.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of SLC25A20 increases acylcarnitine transport capacity, useful for gain-of-function studies and for testing whether enhanced transport protects against lipid stress.
How EDITGENE Supports O-acyl-L-carnitine transmembrane transporter activity Research
Researchers studying O-acyl-L-carnitine transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in transport, fatty acid oxidation, or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of genes associated with GO:0015227.
Contact EDITGENE today to design your custom CRISPR model for O-acyl-L-carnitine transmembrane transporter activity research.
Frequently Asked Questions About O-acyl-L-carnitine transmembrane transporter activity
What is O-acyl-L-carnitine transmembrane transporter activity?
It is a molecular function (GO:0015227) that moves acylcarnitine across a membrane, essential for fatty acid transport into mitochondria.
What genes are involved in O-acyl-L-carnitine transmembrane transporter activity?
Key genes include SLC25A20 (CACT), CPT1A, CPT2, and SLC25A29, which facilitate or regulate acylcarnitine transport.
What diseases are associated with defects in acylcarnitine transport?
Mutations in SLC25A20 cause carnitine-acylcarnitine translocase deficiency, leading to cardiomyopathy, hypoglycemia, and early death.
How is O-acyl-L-carnitine transmembrane transporter activity measured?
It is measured using radiolabeled transport assays, LC-MS/MS acylcarnitine profiling, and functional mitochondrial respiration assays.
What is the role of SLC25A20 in fatty acid oxidation?
SLC25A20 exchanges acylcarnitine for carnitine across the inner mitochondrial membrane, allowing fatty acids to enter for beta-oxidation.
Can CRISPR be used to study acylcarnitine transporters?
Yes, CRISPR knockout, knock-in, and overexpression models enable precise functional studies of genes like SLC25A20.
What are the symptoms of carnitine-acylcarnitine translocase deficiency?
Symptoms include hypoketotic hypoglycemia, hyperammonemia, cardiomyopathy, muscle weakness, and sudden infant death.
How does acylcarnitine transport relate to cancer metabolism?
Cancer cells may rely on fatty acid oxidation, and acylcarnitine transporters support this by supplying substrates to mitochondria.
What is the difference between CPT1 and CACT?
CPT1 forms acylcarnitine on the outer mitochondrial membrane, while CACT (SLC25A20) transports it across the inner membrane.
Where can I find validated CRISPR models for acylcarnitine transporter genes?
EDITGENE offers custom knockout, knock-in, and overexpression models for SLC25A20 and related genes.
Conclusion
O-acyl-L-carnitine transmembrane transporter activity (GO:0015227) is a fundamental molecular function that bridges lipid metabolism and mitochondrial energy production. Its central role in fatty acid oxidation makes it a critical focus for understanding metabolic diseases, cancer, and drug interactions. Advances in CRISPR-based models and analytical techniques continue to illuminate the regulation and dysfunction of this transport activity, offering new avenues for therapeutic intervention.
References
- 1. Bi Y et al.. 2023. Transporter-mediated Natural Product-Drug Interactions.. Planta Med 89(2):119-133 PMID: 35304735
